Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TPST Tempest Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TPST
Price (delayed)
$6.895
Market cap
$25.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$17.98
Enterprise value
$16.98M
Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct
Highlights
Tempest Therapeutics's debt has decreased by 36% YoY and by 15% from the previous quarter
The EPS has grown by 19% YoY and by 8% from the previous quarter
The net income has plunged by 51% YoY and by 7% from the previous quarter
The quick ratio is down by 46% year-on-year and by 23% since the previous quarter
Key stats
What are the main financial stats of TPST
Market
Valuations
Earnings
Shares outstanding
3.68M
Market cap
$25.39M
Enterprise value
$16.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$44.99M
Net income
-$44.8M
EBIT
-$43.69M
EBITDA
-$42.18M
Free cash flow
-$34.14M
Per share
Balance sheet
Liquidity
EPS
-$17.98
EPS diluted
-$17.98
Free cash flow per share
-$9.93
Book value per share
$3.18
Revenue per share
$0
TBVPS
$9.36
Total assets
$32.16M
Total liabilities
$21.03M
Debt
$13.11M
Equity
$11.13M
Working capital
$9.26M
Debt to equity
1.18
Current ratio
1.7
Quick ratio
1.63
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-119.7%
Return on equity
-305.5%
Return on invested capital
-316.8%
Return on capital employed
-230.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TPST stock price
How has the Tempest Therapeutics stock price performed over time
Intraday
1.25%
1 week
9.44%
1 month
-1.36%
1 year
-84.21%
YTD
-36.45%
QTD
-28.1%
Financial performance
How have Tempest Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.99M
Net income
-$44.8M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 52% YoY and by 7% QoQ
The net income has plunged by 51% YoY and by 7% from the previous quarter
Price vs fundamentals
How does TPST's price correlate with its fundamentals
Growth
What is Tempest Therapeutics's growth rate over time
Valuation
What is Tempest Therapeutics stock price valuation
P/E
N/A
P/B
2.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 19% YoY and by 8% from the previous quarter
The equity has contracted by 46% YoY and by 42% from the previous quarter
The price to book (P/B) is 21% lower than the last 4 quarters average of 2.7 but 19% higher than the 5-year quarterly average of 1.8
Efficiency
How efficient is Tempest Therapeutics business performance
TPST's return on invested capital has dropped by 174% year-on-year and by 30% since the previous quarter
The company's return on assets has shrunk by 52% YoY and by 16% QoQ
The ROE has contracted by 31% YoY and by 24% from the previous quarter
Dividends
What is TPST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TPST.
Financial health
How did Tempest Therapeutics financials performed over time
The company's total assets is 53% higher than its total liabilities
The quick ratio is down by 46% year-on-year and by 23% since the previous quarter
The current ratio has declined by 46% year-on-year and by 23% since the previous quarter
Tempest Therapeutics's debt is 18% more than its equity
The debt to equity is up by 48% since the previous quarter and by 19% year-on-year
The equity has contracted by 46% YoY and by 42% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.